Insmed vs Lakefront Biotherapeutics
INSM and LKFT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and LKFT compare
Lakefront Biotherapeutics grew revenue faster over the last twelve months (304% versus 240% for Insmed).
Lakefront Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 28.8% compared with −39.9% at Insmed.
Insmed scores higher on the StockData Score (8 against 7 for Lakefront Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | LKFT |
|---|---|---|
| Size and price | ||
| Market cap | $26.6B | – |
| Share price | $121.16 | $33.98 |
| Change, 1 year | −37.7% | 5.2% |
| Change, 5 years | 298% | −34.0% |
| Beta (5Y) | 0.76 | 0.57 |
| Employees | 1,664 | 452 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 17.5× | – |
| P/B | 36.6× | – |
| FCF yield | −2.4% | – |
| Fair value | $60.58 | – |
| Margin of safety | −100% | – |
| Growth | ||
| Revenue growth (TTM) | 240% | 304% (better) |
| Revenue growth, 5Y average | 29.8% (better) | 18.4% |
| Net income growth (TTM) | – | 333% |
| EPS growth (TTM) | – | 335% |
| Profitability | ||
| Gross margin | 84.4% | 97.3% (better) |
| Operating margin | −37.1% | 26.5% (better) |
| Net margin | −39.9% | 28.8% (better) |
| FCF margin | −41.3% | −24.4% (better) |
| Return on equity | −72.5% | – |
| Financial health | ||
| Debt / equity | 0.76 | – |
| Interest coverage | −6.9× | 285× (better) |
| Current ratio | 2.86 | 20.15 (better) |
| Altman Z-score | 7.36 | – |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 102% | 48.6% |
| Held by insiders | 0.89% | 45.1% |
| Insider net buying, 12 months | −$133M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.5% | – |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- LKFT stock overview
- LKFT income statement
- LKFT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.